US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
BridgeBio Pharma, Inc. - Common Stock
(NQ:
BBIO
)
67.25
+0.34 (+0.51%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BridgeBio Pharma, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
June 22, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
May 27, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches
↗
May 13, 2026
BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three...
Via
MarketBeat
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
May 12, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma (NASDAQ:BBIO) Q1 2026 Revenue Beat Driven by Attruby Sales Surge, Shares Jump
↗
May 07, 2026
Via
Chartmill
BridgeBio Pharma Inc (NASDAQ:BBIO) Posts Q4 Revenue Beat on Heart Drug Surge, Eyes Multiple 2026 NDA Submissions
↗
February 24, 2026
Via
Chartmill
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
May 11, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 08, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio (BBIO) Q1 2026 Earnings Transcript
↗
May 08, 2026
BridgeBio (BBIO) Q1 2026 Earnings Transcript
Via
The Motley Fool
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
May 07, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Participate in May and June Investor Conferences
May 06, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
May 06, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
May 05, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
May 04, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
April 30, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio (BBIO) Q2 2025 Earnings Transcript
↗
April 28, 2026
BridgeBio (BBIO) Q2 2025 Earnings Transcript
Via
The Motley Fool
BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White
April 28, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 22, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
April 13, 2026
In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL...
Via
MarketMinute
Topics
Economy
BridgeBio Pharma Inc (NASDAQ:BBIO) Shows High Technical and Setup Ratings Ahead of Potential Breakout
↗
April 11, 2026
BridgeBio Pharma (BBIO) shows a strong technical uptrend with a high-quality consolidation pattern, signaling a potential breakout opportunity for traders.
Via
Chartmill
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
March 30, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
March 30, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
March 23, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 20, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
March 11, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
March 04, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio (BBIO) Q4 2025 Earnings Call Transcript
↗
February 24, 2026
BridgeBio (BBIO) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
February 24, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio to Participate in March Investor Conferences
February 23, 2026
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites
↗
February 17, 2026
Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day.
Via
Stocktwits
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
